Charles L. Vogel, M.D.
- Office: 954-571-0111
- Fax: 954-571-0118
- American Board of Internal Medicine
- American Board of Internal Med-Medical Oncology
- Hematology/Oncology - Internal Medicine
- Internal Medicine
- Professor of Medicine Clinical Educator Track
Best Doctors in America- Every year since inception
Invited Participant Secretary of Health
United States Public Health Service
National Institutes of Health: Bethesda, MD
Grady Memorial Hospital: Atlanta, GA
Grady Memorial Hospital: Atlanta, GA
1964 Graduate School
Yale University: New Haven, CT
- Girish S, Gupta M, Wang B, Lu D, Krop IE, Vogel CL, Burris III HA, LoRusso PM, Yi J-H, Saad O, Tong B, Chu W, Holden S, Joshi A. Clinical pharmacology of Trastuzumab Emtansine (T-DM): an antibody-drug conjugate in development for the treatment of her-2 positive cancer. submitted 2011 Cancer Chem. Pharm (Pub Med) Jan 20, 2012
- Montero AJ, and Vogel CL. Fighting fire with fire: Rekindling the bevacizumab debate. NEJM 366: 374,375, 2012
- Mahtani R, Stein A, Vogel CL. High dose estrogen as salvage hormonal therapy for highly refractory metastatic breast cancer: A retrospective review. Clinical Therapeutics 31: 2371-2378, 2009
- Vogel CL, Cobleigh MA, Tripathy D, Harris LN, Fehrenbacher L, Slamon DJ, Ash M, Novotny WF, Stewart S, Shak S. Efficacy and safety of Trastuzumab (Herceptin) as a single agent in first-line treatment of Her-2-overexpressing metastatic breast cancer. J Clin Oncol 20:719-726, 2002.
- Vogel CL, Martin M, Nabholtz JM. Docetaxel-doxorubicin-cyclophosphamide versus 5-Fluorouracil-doxorubicin-cyclophosphamide for the adjuvant treatment of node-positive breast cancer: Interim results from the BCIRG 001 trial. Cancer Conference Highlights. Advances in Breast Cancer 4:(No. 4) 2-8 Sept 2002.
- Ahn E, Vogel CL. Dual Her-2-targeted approaches in Her 2-positive breast cancer. Breast Cancer Treatment Research 131:371-383, 2012
- Pollan M, Pajares B, Martin M, Mackey J, Lluch A, Ruiz A, Vogel C, Borrego MR, Calvo L, Pienkowski T, Lescure AR, Segui MA, Tredan O, Anton A, Ramos M, Camara MC, Roddriguez-Martin C, Carrasco E, Alba E. The effect of obesity on prognosis in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to intrinsic subtypes. Poster ASCO 2013.
- Michiels S, Pugliano L, Grun D, Barinoff J, Cameron D, Cobleigh M, DiLeo A, Johnston S, Gasparini G, Kaufman B, Marty M, Nekjudova V, Paluch-Shimon S, Penault-Llorca F, Slamon D, Vogel C, von Minckwitz G, Buyse M, Piccart M. Progression –free survival (PFS) as surrogate endpoints for overall survival (OS) in clinical trials of Her-2-targeted agents in HER2-positive metastatic breast cancer (MBC): an individual patient data (IPD) analysis. Poster ASCO 2013
- Love N: Moderator. Audiotape Gonzalez-Angulo AM, Gradishar WJ, Hayes DF, Krop IE, Linden HM, Mamounas EP, Miller KD, Vogel CL. Breast Cancer Update Think Tank. Issue #1 2012
- Mayer E, Miller K, O’Shaughnessy J, Dickler M, Vogel C, Leyland-Jones, B, Steelman L, Robinson M, Kurzyama N, Agarwal S. Tivozanib in combination with paclitaxel vs placebo in patients with locally advanced or metastatic triple-negative breast cancer. Ca Res 72 (#24, suppl 3) OT-2-3-11, pg 43s, 2012
- Ambros T, Zeichner S, Zaravinos J, Montero A, Ahn E, Mani A, Kronish L, Mahtani R, Vogel CL. The efficacy and toxicity of low-dose capecitabine in Her-2 negative breast cancer. Ca Res: 72 (#24, suppl 3) P-1-12-03, pg 192s, 2012
- Kaufman PA, Bloom K, Burris H, Gralow JR, Mayer M, Pegram M, Rugo HS, Swain SM, Yardley DA, Chau M, Lalla D, Yoo B, Brammer MG, Vogel CL. Assessing the discordance rate between local and central Her2 testing in women with Her2-negative breast cancer. Cancer 6/2014: DOI: 10, 1002/cmcn. 28710
- Ambros, T, Zeichner SB, Zaravinos J, Montero AJ, Ahn E, Mani A, Kronish L, Mahtani RL, Vogel CL. A retrospective study evaluating a fixed low dose capecitabine mono therapy in women with Her-2 negative metastatic breast cancer. Breast Ca Res Treat 146:7-14, 2014
Charles Vogel, MD is a board certified medical oncologist. His clinical and research interests involve all medical aspects of breast cancer treatment including anti-hormonal therapy, chemotherapy and "targeted therapy." During his 35 years of breast cancer research, he has participated in clinical trials of virtually every medical breast cancer treatment currently available. He was one of the clinical trial pioneers in Trastuzumab (Herceptin) therapy and more recently with Bevacizimab (Avastin) and Lapatanib (Tykerb). He was also one of the early pioneers in the development of clinical trials from within community practice. Dr. Vogel continues his interest in breast cancer clinical trials both through his involvement with the Breast Site Group of the Sylvester Comprehensive Cancer Center and through similar interactions with community oncologists within the Cancer Research Network.